Tag Archive 'terapia combinada'

Lunes 9 / julio / 2012

Losartan/hydrochlorothiazide combination vs. high-dose losartan in patients with morning hypertension—a prospective, randomized, open-labeled, parallel-group, multicenter trial

Filed under: investigaciones — Mario Hernández Cueto — julio 9th, 2012 — 8:46

Losartan/hydrochlorothiazide combination vs. high-dose losartan in patients with morning hypertension—a prospective, randomized, open-labeled, parallel-group, multicenter trial

Por: Tamenobu Ueda, Hisashi Kai y Tsutomu Imaizumi1 on behalf of the MAPPY Study Investigators. Hypertension Research (2012) 35, 708–714.

investigaciones1

The treatment of morning hypertension has not been established. We compared the efficacy and safety of a losartan/hydrochlorothiazide (HCTZ) combination and high-dose losartan in patients with morning hypertension. A prospective, randomized, open-labeled, parallel-group, multicenter trial enrolled 216 treated outpatients with morning hypertension evaluated by home blood pressure (BP) self-measurement. Patients were randomly assigned to receive a combination therapy of 50 mg losartan and 12.5 mg HCTZ (n=109) or a high-dose therapy with 100 mg losartan (n=107), each of which were administered once every morning.

Comentarios desactivados

Martes 24 / abril / 2012

Combination therapy for hypertension in the elderly: a sub-analysis of the Combination Therapy of Hypertension to Prevent Cardiovascular Events (COPE) Trial.

Filed under: factores de riesgo — Mario Hernández Cueto — abril 24th, 2012 — 13:12

investigaciones1Combination therapy for hypertension in the elderly: a sub-analysis of the Combination Therapy of Hypertension to Prevent Cardiovascular Events (COPE) Trial.

Por: Toshio Ogihara, Masunori Matsuzaki, Seiji Umemoto, Hiromi Rakugi, Hiroaki Matsuoka, Kazuyuki Shimada, Jitsuo Higaki, Sadayoshi Ito, Akira Kamiya, Hiromichi Suzuki, Yasuo Ohashi, Kazuaki Shimamoto y Takao Saruta for the Combination Therapy of Hypertension to Prevent Cardiovascular Events Trial Group. Hypertension Research (2012) 35, 441–448.

La terapia combinada de la hipertensión para prevenir los eventos cardiovasculares  ensayo COPE, demostró que los bloqueadores de los canales de calcio (benidipine) en terapias combinadas con un bloqueador del receptor de angiotensina (ARB), un bloqueador ß-, o un diurético tiazida (tiazida) fueron igual de eficaces en la prevención de eventos cardiovasculares y la consecución del objetivo de presión arterial (BP, 140/90 mm Hg).

Comentarios desactivados